DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Core Insights - DBV Technologies will participate in the AAAAI/WAO Joint Congress from February 28 to March 3, 2025, in San Diego, CA, showcasing its research on the VIASKIN® peanut patch [1][5] Group 1: Clinical Study Results - Dr. David Fleischer will present Month 60 efficacy and safety results from the PEOPLE study, which involved peanut-allergic children aged 4-11 years treated with the VIASKIN® peanut patch for up to 60 months [2][9] - The percentage of treatment responders increased from 39.1% at PEPITES completion to 73.3% at Month 60, indicating significant improvement in treatment efficacy over time [7] - Approximately 66.7% of participants achieved an eliciting dose (ED) of 1,000 mg of peanut protein at Month 60, compared to 33.3% at PEPITES completion [7] Group 2: Safety and Compliance - Most treatment-emergent adverse events (TEAEs) were mild to moderate local skin reactions, which decreased in frequency and severity over the study period [7] - Treatment compliance remained high at 93.1% over five years, suggesting strong adherence to the treatment regimen [6][7] Group 3: Future Directions - DBV Technologies is committed to completing studies for regulatory submissions targeting toddlers aged 1-3 years and children aged 4-7 years [8] - The company aims to demonstrate the long-term efficacy and safety of the VIASKIN® peanut patch as a potential breakthrough treatment for peanut allergies [6][11]